SCOTT HINKLE — Lobbyist Profile | Poliscope

SCOTT HINKLE

Filings

Clients

Firms

Years active

2026–2026

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
BRIDGEBIO PHARMA, INC.	2	2026

Lobbying firms

Firm	Filings	Years
BRIDGEBIO PHARMA, INC.	2	2026

Bills explicitly cited in this lobbyist’s assigned issues (5)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 10359

Priority for Pediatric Cures Act

Client: BRIDGEBIO PHARMA, INC. · Firm: BRIDGEBIO PHARMA, INC.

Open original LDA filing ↗

Cited source text

Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act Priority for Pediatric Cures Act (H.R.10359)

H.R. 1532

Scientific EXPERT Act of 2025

Client: BRIDGEBIO PHARMA, INC. · Firm: BRIDGEBIO PHARMA, INC.

Open original LDA filing ↗

Cited source text

Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act

Original LDA source filings (2)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

BRIDGEBIO PHARMA, INC. via BRIDGEBIO PHARMA, INC.

2026 · third_quarter · Q3

Firm income: —Client expense: $510,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act Priority for Pediatric Cures Act (H.R.10359)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BRIDGEBIO PHARMA, INC. via BRIDGEBIO PHARMA, INC.

2026 · second_quarter · Q2

Firm income: —

Source: Senate LDA